What Justin Stindt Consultants does

Justin Stindt Consultants (J.Stindt Consultants / JSC) is a privately held boutique consulting firm founded in 2014 and headquartered in Cologne (Germany), with additional offices in Paris and Zug (Switzerland) and a stated USA presence. It provides strategy and market access advisory services to pharmaceutical, biotech, medical device, and e-health clients, organized across three pillars: Global Pricing & Reimbursement (strategy, pathway advisory, analogue benchmarking, international reference pricing), Pricing & Reimbursement Submissions (dossiers, early access programs, health economic modeling, systematic literature reviews), and Payer & HTA Engagement (scientific advice, advisory boards, payer value propositions, stakeholder mapping, training). Services are delivered by senior consultants who engage directly with clients across Europe, the US, and Japan, with named senior expertise in EU HTA processes and EU HTA Regulation 2021/2282 (including Joint Clinical Assessments, PICO anticipation, parallel EMA-HTA scientific advice, and MFN scenario planning).

The firm's underlying technology footprint is limited to a multilingual (EN, FR, DE, ES, IT) content-led marketing site, newsletter distribution, and a social media presence; JSC does not develop or resell proprietary software, has no public APIs, and reports no AI/ML capabilities. Its competitive basis is human expertise, regulatory process knowledge across HTA bodies (NICE, G-BA, HAS, AIFA, AEMPS), and a payer/clinical-expert network built via hundreds of prior engagements, with multiple Fortune 500 pharma clients (Astellas, Daiichi Sankyo, Bristol Myers Squibb, Recordati, Toray, Taiho Oncology, Ionis, argenx, Indivior, Eiger, HS Life Sciences, Bene-Arzneimittel) and biotech clients (MED'INN'PHARMA, Choice for Women) evidenced through public testimonials.

JSC operates a project-based, quote-driven professional services revenue model with no publicly disclosed pricing or revenue; it is founder-owned by Justin Stindt (CEO/Managing Director), with Javier Arribas promoted to equity partner in July 2026 as the first partner expansion. The legal entity is Justin Stindt Consulting GmbH (registered with AG Köln, HRB 82988). Customer engagement is sales-led, initiated via direct contact, website, and email, with no external institutional investment, no M&A, and no disclosed funding rounds.

Name

Justin Stindt Consultants

Legal name

Justin Stindt Consulting GmbH

Website

https://jstindt.com

Company type

Private

Founded year

2014

Operating status

Operating

Headcount range

11–50 employees

Short description

Justin Stindt Consultants is a founder-owned boutique consultancy providing market access, pricing & reimbursement, and payer/HTA engagement advisory to pharmaceutical, biotech, medical device, and e-health clients across Europe, the UK, Switzerland, and the United States.

Ownership category

akta.pro rank

Product category

Pharmaceutical Market Access Consulting

NAICS

Management Consulting Services (54161)

SIC

Services-Management Consulting Services (8742)

akta.pro primary industry

Risk, Compliance & Internal Controls Consulting (BPAHACAJ)

akta.pro secondary industry

Operations & Process Improvement Consulting (BPAHACAB)

Keywords

• Market access consulting
• Pricing and reimbursement
• Pharma strategy advisory
• HTA engagement
• Biotech market entry

Headquarters

HQ city

Zug

HQ country

Switzerland

HQ region

Europe

Offices3 records

Markets served

GTM type

B2B

Offering type

Services

Cost components

Personnel, Operations, Marketing or Sales, Technology or R&D, Infrastructure

Revenue model

1. Strategy & Market Access Advisory Services: Professional consulting services providing market access strategy, pricing & reimbursement strategy, and payer/HTA engagement support to pharmaceutical, biotech, medical device, and e-health companies. Services include pricing & reimbursement strategies, dossier preparation, health economic modelling, scientific advice support, and payer advisory boards.

Go-to-market motion2 records

Distribution channels1 record

Marketing channels4 records

Core offering

Justin Stindt Consultants is a boutique consulting firm providing strategy and market access advisory services to pharmaceutical, biotech, medical device, and e-health clients. The firm delivers global pricing and reimbursement strategy, dossier preparation, health economic modelling, payer and HTA engagement, and payer advisory boards across major EU markets, the USA, and Japan. Services are tailored to each client and delivered directly by senior consultants who may be granted power of attorney to represent clients before payers and HTA bodies.

Product overview

Justin Stindt Consultants is a market access and pricing strategy consultancy firm providing advisory services to pharmaceutical, biotech, medical device, and e-health companies. The firm operates a portfolio of consulting service modules organized across three main pillars: Global Pricing & Reimbursement (encompassing strategy development, pathway advisory, analogue benchmarking, and international reference pricing), Pricing & Reimbursement Submissions (including dossier preparation, early access programs, health economic modeling, and systematic literature reviews), and Payer & HTA Engagement (covering scientific advice, advisory boards, stakeholder mapping, and market access training). Additional specialized offerings include EU Joint Clinical Assessment dossier support, PICO anticipation services for EMA submissions, and biotech-specific market access advisory. The firm does not offer a software product but rather delivers professional consulting engagements tailored to client needs across US and European markets.

Differentiator

Problem solved

Functional benefit

Products and services

• Global Pricing & Reimbursement Strategy Services

Quantifiable outcome

• Enabling patient access to innovative medicines and medical technologies across multiple countries with reimbursement at sustainable prices

Named customers14 records

Segments4 records

Ideal customer profiles4 records

Technology focussed No

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Scale indicators5 records

Recent moves6 records

Expansion highlights8 records

Broad incumbents

• McKinsey & Company (Pharma & Medical Products Practice): Top-tier strategy consultancy with a large pharma/biotech practice covering market access, pricing and launch strategy — competes with JSC on the largest global launches and corporate-level P&R strategy engagements.
• IQVIA: Global healthcare data and consulting leader with extensive market access, RWE and HTA capabilities; competes with JSC across the full market access value chain, particularly on multi-country launches requiring RWE infrastructure and global reach.
• PharmaLex (Cencora): Regulatory affairs and market access consultancy that supports dossier submissions, HTA interactions and P&R strategy for pharma/biotech — directly competes with JSC on dossier preparation and scientific advice, with deeper resourcing and broader service lines.
• Charles River Associates: Global consulting firm with a Life Sciences practice advising on pricing, market access, commercial strategy and transactions — overlapping with JSC's market access and commercial analytics work for pharma/biotech.
• Evidera (part of Cencora/PharmaLex): Large-scale provider of market access, health economics, RWE and HTA services to biopharma — overlapping with JSC's P&R, HTA scientific advice and dossier offerings but with substantially broader scope, proprietary data assets and global delivery.

Direct peers

• Putnam Associates: Strategy consulting firm focused on biopharma and medtech commercial, pricing and market access engagements; comparable boutique senior-led model serving similar pharma/biotech buyers on payer strategy and launch readiness.
• SmartAnalyst: Specialist market access and pricing strategy consultancy serving global pharma and biotech clients — closely comparable on P&R strategy, payer evidence generation, and HTA-related advisory work, including for rare disease assets.
• MAP BioPharma: UK-based boutique consultancy specializing in market access, pricing and reimbursement strategy for pharma, biotech and medtech — overlapping closely with JSC's core P&R advisory, dossier preparation and HTA engagement offerings across European markets.
• Health Advances: Strategy consulting boutique focused exclusively on healthcare and life sciences, advising on market access, commercial strategy and BD&L — comparable boutique model serving pharma/biotech on P&R and evidence-generation strategy.

Regional players

• Ayming: European consultancy with regulatory, R&D and market access capabilities serving pharma and medtech — comparable on P&R and regulatory pathway work, particularly across continental European markets where JSC has its strongest footprint.

Market position

Strengths4 records

Weaknesses4 records

Competitive moat4 records

Key risks5 records

Key highlights6 records

Customer concentration

• LinkedInlinkedin.com/company/justin-stindt-consulting

Revenue estimate

Valuation estimate

Number of profiles

Profiles3 records

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Justin Stindt Consultants